Branched-Chain Amino Acid Transamination Inhibition to Modulate Neurotransmitter Homeostasis
Curated pathway from expert analysis
flowchart TD
A["BCAT1/BCAT2<br/>Hypothesis Target"]
B["Pathway Dysregulation<br/>Cited Mechanism"]
C["Cellular Response<br/>Stress or Clearance Change"]
D["Neural Circuit Effect<br/>Synapse/Glia Vulnerability"]
E["Neurodegeneration<br/>Disease-Relevant Outcome"]
A --> B
B --> C
C --> D
D --> E
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style B fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9aNo linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for BCAT1 yet. Search RCSB →
Median TPM across 13 brain regions for BCAT1/BCAT2 from GTEx v10.
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for BCAT1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF CRISPR-Cas9 editing is used to knock down BCAT2 in SH-SY5Y neuroblastoma cells (≥70% knockdown efficiency), THEN intracellular tyrosine and tryptophan will accumulate ≥2-fold while dopamine and ser | Accumulation of aromatic amino acid precursors (tyrosine, tryptophan) and corresponding decrease in downstream monoamine neurotransmitters | — no observation — | pending | 0.35 |
| IF primary mouse cortical neurons are treated with the BCAT inhibitor gabapentin (100 µM, 48h) or vehicle control, THEN glutamate and GABA levels will decrease by ≥25% compared to vehicle controls as | Significant reduction in extracellular glutamate and GABA concentrations (≥25% decrease) following BCAT inhibition in neuronal cultures | — no observation — | pending | 0.45 |